13 September 2022>: Original Paper
Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analysis Using the Korean Organ Transplantation Registry Database
Woo-Hyoung Kang 1ABCDE , Shin Hwang 1ABCDEFG* , Jong Man Kim 2BCE , Kwang-Woong Lee 3BDE , Dong Jin Joo 4BDE , Young Kyoung You 5BDE , Je Ho Ryu 6BCE , Bong-Wan Kim 7BDE , Donglak Choi 8BDE , Dong-Sik Kim 9BDE , Yang Won Nah 10BDEDOI: 10.12659/AOT.936937
Ann Transplant 2022; 27:e936937
Table 2 Comparison of diagnostic predictability of tumor markers for hepatocellular carcinoma.
Group | AFP >7.5 ng/mL | PIVKA-II >40 mAU/mL | ||
---|---|---|---|---|
Sensitivity | Specificity | Sensitivity | Specificity | |
All | 44.9% | 79.7% | 62.6% | 46.9% |
HBV | 44.4% | 70.6% | 32.9% | 73.6% |
HCV | 58.0% | 89.3% | 49.5% | 64.3% |
ALD | 36.1% | 86.2% | 42.1% | 62.3% |
Other | 47.8% | 74.3% | 42.0% | 62.2% |
AFP – alpha-fetoprotein; PIVKA-II – protein induced by vitamin K absence or antagonist-II; HBV – hepatitis B virus; HCV – hepatitis C virus; ALD – alcoholic liver disease. |